Deborah Charych
Directeur/Bestuurslid bij SKYE BIOSCIENCE, INC.
Vermogen: - $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Deborah Charych
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
| Public Company | Pharmaceuticals: Major | 13 | |
| Subsidiary | Biotechnology | 10 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Deborah Charych via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| E I DU PONT DE NEMOURS AND CO | Chemicals: Agricultural | Corporate Officer/Principal General Counsel | |
| Washington University in St. Louis | College/University | Undergraduate Degree Graduate Degree | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Biotechnology | Corporate Officer/Principal | |
| RIGEL PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| SENOMYX INC. | Food: Specialty/Candy | Chief Executive Officer | |
Venturi Ventures, Inc.
 Venturi Ventures, Inc. Medical SpecialtiesHealth Technology Venturi Ventures, Inc. engages in the development and marketing of its advanced verification of integration dose technology. The company was founded on December 3, 1980 and is headquartered in North Vancouver, Canada. | Medical Specialties | Director/Board Member Director/Board Member | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Naviscan, Inc.
 Naviscan, Inc. Electronic Production EquipmentElectronic Technology Naviscan, Inc. develops, manufactures, and markets organ molecular imaging scanners. The company was founded by Irving Weinberg on January 31, 2006 and is headquartered in San Diego, CA. | Electronic Production Equipment | Chairman | |
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Biotechnology | Chairman | |
| ONCOSEC MEDICAL INCORPORATED | Medical/Nursing Services | Chief Executive Officer Chief Executive Officer Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| RECEPTOS INC | Pharmaceuticals: Major | Director/Board Member | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford University | College/University | Doctorate Degree Graduate Degree | |
| University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
| Vanderbilt University | College/University | Doctorate Degree Graduate Degree | |
| University of California, Davis | College/University | Doctorate Degree Undergraduate Degree | |
| University of California, Irvine | College/University | Masters Business Admin Masters Business Admin | |
| University of Michigan | College/University | Masters Business Admin Masters Business Admin Corporate Officer/Principal | |
| The University of California, San Francisco | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Private Equity Investor | |
| INOVIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO General Counsel | |
| Indian Institute of Technology New Delhi | College/University | Doctorate Degree | |
| FATE THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Chairman Chief Executive Officer | |
| AUSPEX PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member | |
| Rani Durgavati University | College/University | Undergraduate Degree | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Indian Institute of Technology Bombay | College/University | Undergraduate Degree | |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
RuiYi, Inc. (China)
 RuiYi, Inc. (China) BiotechnologyHealth Technology Part of 5AM Venture Management LLC, RuiYi, Inc. (China) is a Chinese company that develops biologic therapies. The company is based in Pudong, China. The CEO of the company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio Sub, Inc., part of 5AM Venture Management LLC from December 11, 2023 on March 22, 2012. | Biotechnology | Chief Executive Officer | |
Progenitor Labs Ltd.
 Progenitor Labs Ltd. Pharmaceuticals: MajorHealth Technology Progenitor Labs Ltd. develops drugs to regenerate specific tissues of the human body in response to injury, disease, and ageing. Its products include ProScreen and CombiCult. The company was founded by Yen Choo on February 12, 2010 and is headquartered in Stevenage, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
| EMERALD HEALTH THERAPEUTICS | Agricultural Commodities/Milling | Director/Board Member Director/Board Member | |
Emerald Health Sciences, Inc.
 Emerald Health Sciences, Inc. Pharmaceuticals: MajorHealth Technology Emerald Health Sciences, Inc. develops cannabinoid pharmaceutical drugs. It targets botanicals including medical & recreational and nutraceutical segments. The company was founded on July 31 2007is headquartered in Victoria, Canada. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Emerald Health Bioceuticals, Inc.
 Emerald Health Bioceuticals, Inc. BiotechnologyHealth Technology Emerald Health Bioceuticals, Inc. engages in the provision of research and development of cannabis-free nutritional supplements that support the body’s endocannabinoid system (ECS). Its products include Endo Omega, Endo OmegaVegan, Endo Immune, Endo Sleep, Endo Bliss, Endo Calm, Endo Inflame, and Endo Brain. The company was founded on March 27, 2015 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman President | |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Chief Operating Officer | |
| CONTINEUM THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| RAYZEBIO, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 42 |
| Canada | 4 |
| India | 4 |
| Verenigd Koninkrijk | 3 |
| China | 2 |
Sectoraal
| Health Technology | 31 |
| Consumer Services | 14 |
| Process Industries | 3 |
| Commercial Services | 2 |
| Consumer Non-Durables | 2 |
Operationeel
| Director/Board Member | 211 |
| Corporate Officer/Principal | 119 |
| Independent Dir/Board Member | 64 |
| Chief Tech/Sci/R&D Officer | 47 |
| President | 39 |
Sterkste connecties
| Insiders | |
|---|---|
| Andrew Schwab | 45 |
| Bharatt Chowrira | 24 |
| Ivan Philip Gergel | 24 |
| Praveen Tyle | 23 |
| R. Greer | 23 |
| Julia Gregory | 22 |
| Paul Grayson | 21 |
| Gail Maderis | 20 |
| Brian Kotzin | 20 |
| Bob Rai | 19 |
| Susan S. Wang | 16 |
| Punit Dhillon | 15 |
| Margaret Dalesandro | 13 |
| Lorianne K. Masuoka | 12 |
| Jeffrey Finer | 12 |
- Beurs
- Insiders
- Deborah Charych
- Bedrijfsconnecties
